Old Port Advisors Sells 3,718 Shares of Haleon plc (NYSE:HLN)

Old Port Advisors trimmed its holdings in shares of Haleon plc (NYSE:HLN) by 17.2% in the fourth quarter, HoldingsChannel reports. The firm owned 17,907 shares of the company’s stock after selling 3,718 shares during the period. Old Port Advisors’ holdings in Haleon were worth $171,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of HLN. FMR LLC increased its stake in shares of Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after buying an additional 5,768,117 shares in the last quarter. Clearbridge Investments LLC increased its position in Haleon by 8.6% in the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after acquiring an additional 3,307,009 shares in the last quarter. Wellington Management Group LLP increased its position in Haleon by 49.9% in the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock valued at $96,833,000 after acquiring an additional 3,046,841 shares in the last quarter. Sculptor Capital LP raised its stake in shares of Haleon by 67.8% in the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after acquiring an additional 3,592,000 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Haleon by 2.7% during the second quarter. Envestnet Asset Management Inc. now owns 7,572,548 shares of the company’s stock worth $62,549,000 after purchasing an additional 196,843 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on HLN. Morgan Stanley raised their price target on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. UBS Group raised Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Haleon currently has a consensus rating of “Buy” and a consensus target price of $10.95.

Haleon Stock Down 1.0 %

Shares of NYSE HLN opened at $9.44 on Friday. Haleon plc has a 1 year low of $7.89 and a 1 year high of $10.80. The firm’s 50-day moving average is $9.64 and its 200-day moving average is $9.63. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $42.73 billion, a PE ratio of 27.76, a price-to-earnings-growth ratio of 2.95 and a beta of 0.28.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.